Click any tag below to further narrow down your results
Links
ChronoMark is a cryptographically verified platform that turns biological de-aging into a competitive sport by standardizing epigenetic clock measurements across fragmented lab providers and creating tamper-proof leaderboards. The business model targets individual biohackers ($29/month), longevity clinics ($299/month), and lab referral commissions as the market shifts from private health tracking to public status-driven competition.
- Biological age claims currently live in a trust vacuum with no standardized scoring or verification, enabling photoshopped reports and cherry-picked scores to spread unchecked on social media.
- Longevity clinics and patients juggle conflicting data formats across multiple lab providers (TruDiagnostic, Neko Health, Function Health), creating a fragmented experience with no unified source of truth.
- ChronoMark's moat comes from multi-year verified history locked into an immutable ledger—users who build reputation on the platform face high switching costs since moving elsewhere means forfeiting their earned status.
- The market timing aligns with hundreds of new longevity clinics opening and thousands of biohackers competing publicly, creating urgent demand for standardized verification infrastructure.
Insilico Medicine used artificial intelligence to develop rentosertib, a drug for chronic lung disease, and early trial data suggests it may also reduce biological markers of aging. The findings come with major caveats: the sample size was small, the drug hasn't been tested in healthy people, and the "aging clocks" used to measure results are scientifically debated.
- Rentosertib reduced biological aging markers across six different AI-based "aging clocks" in a clinical trial, according to results published in Nature Biotechnology.
- The drug was originally developed for idiopathic pulmonary fibrosis (IPF) and has only been tested in sick patients, not healthy ones, so anti-aging claims remain speculative.
- The study has significant limitations: small sample size, unproven reliability of aging clock measurements, and the drug is still years away from regulatory approval even for its primary lung disease indication.
@cremieuxrecueil on X
The post argues that dementia is becoming less common at the same ages than it was decades ago. Its headline example: today's 90-year-olds carry less than half the dementia risk that 90-year-olds did in 1984.
- At a given age such as 70, 75, or 80, dementia prevalence is lower now than it was decades ago.
- Today's 90-year-olds have less than half the dementia risk of those in 1984.
Embracing social connections has been a key factor in the longevity of the author's parents, who are both in their 90s. Despite not adhering to popular wellness trends, their warm interactions with strangers and active social lives have contributed significantly to their health and happiness.
- Benjamin Emanuel lived to 92 and Marsha is still thriving at 92, without meditation, step-tracking, or strict diets
- Their habit of warmly engaging strangers (patients, people met while traveling) seems to have been a bigger health factor than conventional wellness trends
- Emanuel, drawing on his own longevity research, argues casual social connection may matter more for health than diet or supplements
Withings introduces the Body Scan 2, a $600 smart scale designed to provide comprehensive health insights by measuring over 60 biomarkers related to longevity and chronic illness risk. The device, equipped with medical-grade technologies, aims to help users spot early signs of health issues and make lifestyle adjustments for better long-term health outcomes.
- The Body Scan 2 costs $600 and measures over 60 biomarkers tied to longevity and chronic illness risk, including hypertension and early glycemic dysregulation
- It uses 8 embedded electrodes plus 4 in a handle/pull-up bar to generate a "Health Trajectory" score via the Withings app
- Launching Q2 2026, it's still pending FDA clearance for certain metrics
- Withings claims GDPR/HIPAA-compliant data privacy as part of the pitch